Suppr超能文献

氟西汀与曲唑酮:疗效及兴奋-镇静作用

Fluoxetine versus trazodone: efficacy and activating-sedating effects.

作者信息

Beasley C M, Dornseif B E, Pultz J A, Bosomworth J C, Sayler M E

机构信息

Division of Clinical Neurosciences, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Ind. 46285.

出版信息

J Clin Psychiatry. 1991 Jul;52(7):294-9.

PMID:2071559
Abstract

BACKGROUND

The efficacy and safety of fluoxetine (N = 65; median sustained dose, 20 mg/day) and of trazodone (N = 61; median sustained dose, 250 mg/day) were compared in a trial in outpatients with major depressive episode. The incidence and temporal patterns of activation and sedation were also assessed.

METHOD

Men and women who met DSM-III criteria for nonpsychotic major depressive episode (but with a current episode greater than or equal to 4 weeks) and had a 21-item Hamilton Rating Scale for Depression (HAM-D21) score greater than 20 were selected. After single-blind placebo was administered for 1 week, eligible patients were randomized to double-blind fluoxetine or trazodone treatment for up to 6 weeks. Efficacy (HAM-D21, Clinical Global Impressions Scales for Severity and Improvement, Patient Global Impressions Scale for Improvement, Guild Memory Test) and adverse events were evaluated weekly.

RESULTS

The HAM-D21 score improved within both treatment groups (p less than .001). The groups were similar with respect to endpoint mean HAM-D21 improvement. For individual adverse events that developed or worsened during therapy, more fluoxetine-treated patients reported rhinitis and tremor (p less than or equal to .05), while more trazodone-treated patients reported somnolence and dizziness (p less than or equal to .05). More combined events suggesting activation (agitation, anxiety, nervousness, insomnia) were reported with fluoxetine than with trazodone (15.4% vs. 3.3%, p less than or equal to .05), while more combined events suggesting sedation (somnolence, asthenia) were reported with trazodone than with fluoxetine (42.6% vs. 21.5%, p less than or equal to .05). Discontinuation rates for activation and sedation did not differ between treatments. Numerically, more sedation (21.5%) than activation (15.4%) was reported with fluoxetine.

CONCLUSIONS

There was little clinical difference between treatments with regard to efficacy and safety. The occurrence and temporal patterns of activation and sedation differed within and between treatments.

摘要

背景

在一项针对重度抑郁发作门诊患者的试验中,比较了氟西汀(N = 65;持续剂量中位数,20毫克/天)和曲唑酮(N = 61;持续剂量中位数,250毫克/天)的疗效和安全性。还评估了激活和镇静的发生率及时间模式。

方法

选择符合DSM - III非精神病性重度抑郁发作标准(但当前发作持续时间大于或等于4周)且汉密尔顿抑郁量表21项版(HAM - D21)评分大于20的男性和女性。在给予单盲安慰剂1周后,符合条件的患者被随机分配至双盲氟西汀或曲唑酮治疗组,为期6周。每周评估疗效(HAM - D21、临床总体印象严重程度和改善量表、患者总体印象改善量表、韦氏记忆测验)和不良事件。

结果

两个治疗组的HAM - D21评分均有所改善(p <.001)。两组在终点时HAM - D21平均改善程度方面相似。对于治疗期间出现或加重的个体不良事件,更多接受氟西汀治疗的患者报告有鼻炎和震颤(p≤.05),而更多接受曲唑酮治疗的患者报告有嗜睡和头晕(p≤.05)。与曲唑酮相比,氟西汀治疗的患者报告更多提示激活的合并事件(激动、焦虑、紧张、失眠)(15.4%对3.3%,p≤.05),而与氟西汀相比,曲唑酮治疗的患者报告更多提示镇静的合并事件(嗜睡、乏力)(42.6%对21.5%,p≤.05)。治疗之间激活和镇静的停药率无差异。从数字上看,氟西汀报告的镇静(21.5%)多于激活(15.4%)。

结论

在疗效和安全性方面,治疗之间几乎没有临床差异。激活和镇静的发生情况及时间模式在治疗组内和治疗组间有所不同。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验